Un trastorno que disminuye la calidad de vida | 23 AGO 19


Los mecanismos de inervación y vaciamiento gástrico y sus alteraciones, además del diagnóstico y el tratamiento de la gastroparesia
Autor: Camilleri M, Chedid V, Ford AC, et al. Nature Reviews 2018
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

1. Camilleri, M., Parkman, H. P., Shafi, M. A., Abell, T. L. & Gerson, L. American College of Gastroenterology clinical guideline: management of gastroparesis. Am. J. Gastroenterol. 108, 18–37 (2013). This paper presents the most recent clinical guideline for the management of gastroparesis.

2. Mearin, F. et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastro- enteritis outbreak: one- year follow- up cohort study. Gastroenterology 129, 98–104 (2005).

3. Thumshirn, M. et al. Gastric accommodation in non-ulcer dyspepsia and the roles of Helicobacter pylori infection and vagal function. Gut 44, 55–64 (1999).

4. Tack, J. et al. Clinical and pathophysiological characteristics of acute- onset functional dyspepsia. Gastroenterology 122, 1738–1747 (2002).

5. Vassallo, M., Camilleri, M., Caron, B. L. & Low, P. A. Gastrointestinal motor dysfunction in acquired selective cholinergic dysautonomia associated with infectious mononucleosis. Gastroenterology 100, 252–258 (1991).

6. Pasricha, P. J. & Parkman, H. P. Gastroparesis: definitions and diagnosis. Gastroenterol. Clin. N. Am. 44, 1–7 (2015).

7. Enck, P. et al. Functional dyspepsia. Nat. Rev. Dis. Primers 3, 17081 (2017). This Review presents an excellent synthesis of the state of the art and science in functional dyspepsia.

8. Park, S. Y. et al. Gastric motor dysfunction in patients with functional gastroduodenal symptoms. Am. J. Gastroenterol. 112, 1689–1699 (2017). This paper presents data on different pathophysiological subgroups in almost 1,300 patients with upper GI symptoms.

9. Stanghellini, V. et al. Gastroduodenal disorders. Gastroenterology 150, 1380–1392 (2016). This paper presents the most recent Rome IV document on upper GI dysfunctions and related symptom complexes.

10. Stanghellini, V. & Tack, J. Gastroparesis: separate entity or just a part of dyspepsia? Gut 63, 1972–1978 (2014).

11. Parkman, H. P. et al. Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity. Gastroenterology 140, 101–115 (2011).

12. Soykan, I., Sivri, B., Sarosiek, I., Kiernan, B. & McCallum, R. W. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long- term follow- up of patients with gastroparesis. Dig. Dis. Sci. 43, 2398–2404 (1998).

13. Aleppo, G. et al. Reported gastroparesis in adults with type 1 diabetes (T1D) from the T1D Exchange clinic registry. J. Diabetes Compl. 31, 1669–1673 (2017).

14. Bytzer, P. et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus. Arch. Intern. Med. 161, 1989–1996 (2001).

15. Maleki, D. et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch. Intern. Med. 160, 2808–2816 (2000).

16. Jung, H. K. et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology 136, 1225–1233 (2009). This paper presents a strong epidemiological study on gastroparesis. 17. Rey, E. et al. Prevalence of hidden gastroparesis in the community: the gastroparesis “iceberg”. J. Neurogastroenterol. Motil. 18, 34–42 (2012).

18. Ravella, K. et al. Chronic estrogen deficiency causes gastroparesis by altering neuronal nitric oxide synthase function. Dig. Dis. Sci. 58, 1507–1515 (2013).

19. Showkat Ali, M. et al. Gender and estradiol as major factors in the expression and dimerization of nNOSalpha in rats with experimental diabetic gastroparesis. Dig. Dis. Sci. 57, 2814–2825 (2012).

20. Boaz, M., Kislov, J., Dickman, R. & Wainstein, J. Obesity and symptoms suggestive of gastroparesis in patients with type 2 diabetes and neuropathy. J. Diabetes Compl. 25, 325–328 (2011). 21. Pasricha, P. J. et al. Outcomes and factors associated with reduced symptoms in patients with gastroparesis. Gastroenterology 149, 1762–1774 (2015).

22. Choung, R. S. et al. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am. J. Gastroenterol. 107, 82–88 (2012).

23. Dickman, R. et al. Prevalence of symptoms suggestive of gastroparesis in a cohort of patients with diabetes mellitus. J. Diabetes Compl. 27, 376–379 (2013).

24. Kofod- Andersen, K. & Tarnow, L. Prevalence of gastroparesis- related symptoms in an unselected cohort of patients with type 1 diabetes. J. Diabetes Compl. 26, 89–93 (2012).

25. Almogbel, R. A., Alhussan, F. A., Alnasser, S. A. & Algeffari, M. A. Prevalence and risk factors of gastroparesis- related symptoms among patients with type 2 diabetes. Intl. J. Health Sci. 10, 397–404 (2016).

26. Bharucha, A. E. et al. Delayed gastric emptying is associated with early and long- term hyperglycemia in type 1 diabetes mellitus. Gastroenterology 149, 330–339 (2015). This article presents an important longitudinal study of diabetes complications including gastroparesis.

27. Phillips, L. K., Deane, A. M., Jones, K. L., Rayner, C. K. & Horowitz, M. Gastric emptying and glycaemia in health and diabetes mellitus. Nat. Rev. Endocrinol. 11, 112–128 (2015).

28. Boronikolos, G. C. et al. Upper gastrointestinal motility and symptoms in individuals with diabetes, prediabetes and normal glucose tolerance. Diabetologia 58, 1175–1182 (2015).

29. Jones, K. L. et al. A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus. Am. J. Med. 113, 449–455 (2002).

30. Kong, M. F., Horowitz, M., Jones, K. L., Wishart, J. M. & Harding, P. E. Natural history of diabetic gastroparesis. Diabetes Care 22, 503–507 (1999).

31. Chang, J., Rayner, C. K., Jones, K. L. & Horowitz, M. Prognosis of diabetic gastroparesis—a 25-year evaluation. Diabetes Med. 30, e185–e188 (2013). This important article describes the natural history of diabetic gastroparesis.

32. Wang, Y. R., Fisher, R. S. & Parkman, H. P. Gastroparesis- related hospitalizations in the United States: Trends, characteristics, and outcomes, 1995–2004. Am. J. Gastroenterol. 103, 313–322 (2008).

33. Hirsch, W. et al. Emergency department burden of gastroparesis in the United States, 2006 to 2013.

J. Clin. Gastroenterol. https://doi.org/10.1097/ MCG.0000000000000972 (2017). 34. Wadhwa, V. et al. Healthcare utilization and costs associated with gastroparesis. World J. Gastroenterol. 23, 4428–4436 (2017).

35. Nusrat, S. & Bielefeldt, K. Gastroparesis on the rise: Incidence versus awareness? Neurogastroenterol. Motil. 25, 16–22 (2013).

36. Uppalapati, S. S., Ramzan, Z., Fisher, R. S. & Parkman, H. P. Factors contributing to hospitalization for gastroparesis exacerbations. Dig. Dis. Sci. 54, 2404–2409 (2009).

37. Bielefeldt, K. Regional differences in healthcare delivery for gastroparesis. Dig. Dis. Sci. 58, 2789–2798 (2013).

38. Bielefeldt, K. Factors influencing admission and outcomes in gastroparesis. Neurogastroenterol. Motil. 25, 389–398 (2013).

39. Hyett, B. et al. Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. Gastroenterology 137, 445–452 (2009). This paper provides the details of the morbidity and complications of diabetic gastroparesis.

40. Meyer, J. H., Thomson, J. B., Cohen, M. B., Shadchehr, A. & Mandiola, S. A. Sieving of solid food by the canine stomach and sieving after gastric surgery. Gastroenterology 76, 804–813 (1979).

41. Meyer, J. H., Elashoff, J., Porter- Fink, V., Dressman, J. & Amidon, G. L. Human postprandial gastric emptying of 1-3-millimeter spheres. Gastroenterology 94, 1315–1325 (1988).

42. Grider, J. R. & Makhlouf, G. M. Regulation of the peristaltic reflex by peptides of the myenteric plexus. Arch. Int. Pharmacodyn. Ther. 303, 232–251 (1990).

43. Sanders, K. M., Ward, S. M. & Koh, S. D. Interstitial cells: regulators of smooth muscle function. Physiol. Rev. 94, 859–907 (2014). This important review discusses the pacemaker cells in the GI tract.

44. Grover, M. et al. Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology 140, 1575–1585 (2011).

45. Bernard, C. E. et al. Association of low numbers of CD206-positive cells with loss of ICC in the gastric body of patients with diabetic gastroparesis. Neurogastroenterol. Motil. 26, 1275–1284 (2014).

46. Herring, B. P. et al. Idiopathic gastroparesis is associated with specific transcriptional changes in the gastric muscularis externa. Neurogastroenterol. Motil. 30, e13230 (2018).

47. Stadler, K. Oxidative stress in diabetes. Adv. Exp. Med. Biol. 771, 272–287 (2012).

48. Han, B., Li, X. & Hao, J. The cholinergic anti-inflammatory pathway: an innovative treatment strategy for neurological diseases. Neurosci. Biobehav. Rev. 77, 358–368 (2017).

49. Grover, M. et al. Clinical- histological associations in gastroparesis: results from the Gastroparesis Clinical Research Consortium. Neurogastroenterol. Motil. 24, 531–539 (2012).

50. Hayashi, Y. et al. Hyperglycemia increases interstitial cells of Cajal via MAPK1 and MAPK3 signaling to ETV1 and KIT, leading to rapid gastric emptying. Gastroenterology 153, 521–535 (2017). 51. Choi, K. M. et al. Heme oxygenase-1 protects interstitial cells of Cajal from oxidative stress and reverses diabetic gastroparesis. Gastroenterology 135, 2055–2064 (2008).

52. Yamada, N. et al. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am. J. Hum. Genet. 66, 187–195 (2000).

53. Chen, Y. H. et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum. Genet. 111, 1–8 (2002).

54. Gibbons, S. J. et al. Repeat polymorphisms in the Homo sapiens heme oxygenase-1 gene in diabetic and idiopathic gastroparesis. PLOS ONE 12, e0187772 (2017).

55. Grover, M. et al. Platelet- derived growth factor receptor alpha (PDGFRalpha)-expressing “fibroblastlike cells” in diabetic and idiopathic gastroparesis of humans. Neurogastroenterol. Motil. 24, 844–852 (2012).

56. Bytzer, P. et al. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am. J. Gastroenterol. 97, 604–611 (2002).

57. Gaber, A. O. et al. Changes in gastric emptying in recipients of successful combined pancreas- kidney transplants. Dig. Dis. 9, 437–443 (1991).

58. Coleski, R. & Hasler, W. L. Coupling and propagation of normal and dysrhythmic gastric slow waves during acute hyperglycaemia in healthy humans. Neurogastroenterol. Motil. 21, 492–499 (2009).

59. Fraser, R. J. et al. Hyperglycaemia slows gastric emptying in type 1 (insulin- dependent) diabetes mellitus. Diabetologia 33, 675–680 (1990).

60. Schvarcz, E. et al. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin- dependent diabetes mellitus. Gastroenterology 113, 60–66 (1997).

61. Russo, A. et al. Insulin- induced hypoglycaemia accelerates gastric emptying of solids and liquids in long- standing type 1 diabetes. J. Clin. Endocrinol. Metab. 90, 4489–4495 (2005).

62. Bharucha, A. E., Camilleri, M., Forstrom, L. A. & Zinsmeister, A. R. Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. Clin. Endocrinol. (Oxf.) 70, 415–420 (2009).

63. Holzapfel, A. et al. Gastric emptying in Type II (non-insulin-dependent) diabetes mellitus before and after therapy readjustment: no influence of actual blood glucose concentration. Diabetologia 42, 1410–1412 (1999).

64. Chang, J. et al. A 25-year longitudinal evaluation of gastric emptying in diabetes. Diabetes Care 35, 2594–2596 (2012).

65. Halland, M. & Bharucha, A. E. Relationship between control of glycemia and gastric emptying disturbances in diabetes mellitus. Clin. Gastroenterol. Hepatol. 14, 929–936 (2016).

66. Laway, B. A., Malik, T. S., Khan, S. H. & Rather, T. A. Prevalence of abnormal gastric emptying in asymptomatic women with newly detected diabetes and its reversibility after glycemic control – a prospective case control study. J. Diabetes Compl. 27, 78–81 (2013).

67. Vella, A. et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 56, 1475–1480 (2007).

68. Berry, R. et al. Patterns of abnormal gastric pacemaking after sleeve gastrectomy defined by laparoscopic high- resolution electrical mapping. Obes. Surg. 27, 1929–1937 (2017).

69. Vigneshwaran, B. et al. Impact of sleeve gastrectomy on type 2 diabetes mellitus, gastric emptying time, glucagon- like peptide 1 (GLP-1), ghrelin and leptin in non- morbidly obese subjects with BMI 30–35.0 kg/m2: a prospective study. Obes. Surg. 26, 2817–2823 (2016).

70. Camilleri, M., Lembo, A. & Katzka, D. A. Opioids in gastroenterology: treating adverse effects and creating therapeutic benefits. Clin. Gastroenterol. Hepatol. 15, 1338–1349 (2017).

71. Galligan, J. J. & Akbarali, H. I. Molecular physiology of enteric opioid receptors. Am. J. Gastroenterol. Suppl. 2, 17–21 (2014).

72. Camilleri, M. et al. Dose- related effects of synthetic human beta- endorphin and naloxone on fed gastrointestinal motility. Am. J. Physiol. 251, G147–G154 (1986).

73. Reynolds, J. C., Ouyang, A. & Cohen, S. Evidence for an opiate- mediated pyloric sphincter reflex. Am. J. Physiol. 246, G130–G136 (1984).

74. Parkman, H. P. et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin. Gastroenterol. Hepatol. 9, 1056–1064 (2011).

75. Parkman, H. P. et al. Nausea and vomiting in gastroparesis: similarities and differences in idiopathic and diabetic gastroparesis. Neurogastroenterol. Motil. 28, 1902–1914 (2016). This paper provides an important summary of the features of idiopathic and diabetic gastroparesis observed in the NIH Gastroparesis Consortium study in United States.

76. Parkman, H. P. et al. Early satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and water load testing. Neurogastroenterol. Motil. 29, e12981 (2017).

77. Hasler, W. L. et al. Bloating in gastroparesis: severity, impact, and associated factors. Am. J. Gastroenterol. 106, 1492–1502 (2011).

78. Jehangir, A. & Parkman, H. P. Chronic opioids in gastroparesis: relationship with gastrointestinal symptoms, healthcare utilization and employment. World J. Gastroenterol. 23, 7310–7320 (2017).

79. Maranki, J. L. et al. Predictive factors for clinical improvement with Enterra gastric electric stimulation treatment for refractory gastroparesis. Dig. Dis. Sci. 53, 2072–2078 (2008).

80. Oh, J. J. & Kim, C. H. Gastroparesis after a presumed viral illness: clinical and laboratory features and natural history. Mayo. Clin. Proc. 65, 636–642 (1990).

81. Naftali, T., Yishai, R., Zangen, T. & Levine, A. Post- infectious gastroparesis: clinical and electrogastrographic aspects. J. Gastroenterol. Hepatol. 22, 1423–1428 (2007).

82. Tack, J., Bisschops, R. & Sarnelli, G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 127, 1239–1255 (2004).

This classic paper describes different pathophysiological subgroups in a large number of patients with functional dyspepsia, including delayed emptying and reduced gastric accommodation.

83. Talley, N. J. et al. Impact of chronic gastrointestinal symptoms in diabetes mellitus on health- related quality of life. Am. J. Gastroenterol. 96, 71–76 (2001).

84. Revicki, D. A. et al. Development and validation of a patient- assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment. Pharmacol. Ther. 18, 141–150 (2003).

85. Revicki, D. A. et al. Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index- Daily Diary (GCSI- DD). Neurogastroenterol. Motil. 24, 456–463 (2012).

86. Ricci, J. A. et al. Upper gastrointestinal symptoms in a U. S. national sample of adults with diabetes. Scand. J. Gastroenterol. 35, 152–159 (2000).

87. Hasler, W. L. et al. Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting. Neurogastroenterol. Motil. 25, 427–438 (2013).

88. Tougas, G. et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am. J. Gastroenterol. 95, 1456–1462 (2000).

89. Camilleri, M. et al. Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants. Neurogastroenterol. Motil. 24, 1076–e562 (2012).

90. Szarka, L. A. et al. A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research. Clin. Gastroenterol. Hepatol. 6, 635–643 (2008).

91. Bouras, E. P. et al. SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. Single photon emission computed tomography. Gut 51, 781–786 (2002).

92. Fidler, J. et al. Application of magnetic resonance imaging to measure fasting and postprandial volumes in humans. Neurogastroenterol. Motil. 21, 42–51 (2009).

93. Orthey, P. et al. Intragastric meal distribution during gastric emptying scintigraphy for assessment of fundic accommodation: correlation with symptoms of gastroparesis. J. Nucl. Med. 59, 691–697 (2018).

94. Tack, J., Caenepeel, P., Piessevaux, H., Cuomo, R. & Janssens, J. Assessment of meal induced gastric accommodation by a satiety drinking test in health and in severe functional dyspepsia. Gut 52, 1271–1277 (2003).

95. Grybäck, P. et al. Nationwide standardisation and evaluation of scintigraphic gastric emptying: reference values and comparisons between subgroups in a multicentre trial. Eur. J. Nucl. Med. 27, 647–655 (2000).

96. Desai, A. et al. Reproducibility of gastric emptying assessed with scintigraphy in patients with upper G. I. symptoms. Neurogastroenterol. Motil. 30, e13365 (2018).

97. Vasavid, P. et al. Normal solid gastric emptying values measured by scintigraphy using Asian- style meal: a multicenter study in healthy volunteers. Neurogastroenterol. Motil. 20, 371–378 (2014).

98. Sachdeva, P. et al. Use of a high caloric liquid meal as an alternative to a solid meal for gastric emptying scintigraphy. Dig. Dis. Sci. 58, 2001–2006 (2013).

99. Abell, T. L. et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am. J. Gastroenterol. 103, 753–763 (2008).

100. Zinsmeister, A. R., Bharucha, A. E. & Camilleri, M. Comparison of calculations to estimate gastric emptying half- time of solids in humans. Neurogastroenterol. Motil. 24, 1142–1145 (2012).

101. Ghoos, Y. F. et al. Measurement of gastric emptying rate of solids by means of a carbon- labeled octanoic acid breath test. Gastroenterology 104, 1640–1647 (1993).

102. van de Casteele, M. et al. Oxidative breakdown of octanoic acid is maintained in patients with cirrhosis despite advanced disease. Neurogastroenterol. Motil. 15, 113–120 (2003).

103. Maqbool, S., Parkman, H. P. & Friedenberg, F. K. Wireless capsule motility: comparison of the SmartPill GI monitoring system with scintigraphy for measuring whole gut transit. Dig. Dis. Sci. 54, 2167–2174 (2009).

104. Kuo, B. et al. Comparison of gastric emptying of a nondigestible capsule to a radio- labelled meal in healthy and gastroparetic subjects. Aliment. Pharmacol. Ther. 27, 186–196 (2008).

105. Hasler, W. L. et al. Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis. Neurogastroenterol. Motil. 30, e13196 (2018).

106. Camilleri, M. et al. American Neurogastroenterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice. Neurogastroenterol. Motil. 20, 1269–1282 (2008).

This consensus document discusses methods to measure gastric motor functions.

107. Cogliandro, R. et al. Gastroparesis is more an intestinal than a gastric disease [abstract Sa1567]. Gastroenterology 154 (Suppl. 1), S-313 (2018).

108. Camilleri, M. & Malagelada, J. R. Abnormal intestinal motility in diabetics with the gastroparesis syndrome. Eur. J. Clin. Invest. 14, 420–427 (1984).

109. Stanghellini, V. et al. Chronic intestinal pseudoobstruction: manifestations, natural history and management. Neurogastroenterol. Motil. 19, 440–452 (2007).

110. Chial, H. J., Camilleri, M., Williams, D. E., Litzinger, K. & Perrault, J. Rumination syndrome in children and adolescents: diagnosis, treatment, and prognosis. Pediatrics 111, 158–162 (2003).

111. O’Brien, M. D., Bruce, B. K. & Camilleri, M. The rumination syndrome: clinical features rather than manometric diagnosis. Gastroenterology 108, 1024–1029 (1995). This classical paper describes the symptoms and clinical features of rumination syndrome.

112. Allen, J. H., de Moore, G. M., Heddle, R. & Twartz, J. C. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut 53, 1566–1570 (2004).

113. Sagar, R. C. et al. Cyclic vomiting syndrome is a prevalent and under- recognized condition in the gastroenterology outpatient clinic. Neurogastroenterol. Motil. 30, e13174 (2018).

114. Halland, M., Pandolfino, J. & Barba, E. Diagnosis and treatment of rumination syndrome. Clin. Gastroenterol. Hepatol. 16, 1549–1555 (2018).

115. Stanghellini, V. et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 110, 1036–1042 (1996).

116. Galli, J. A., Sawaya, R. A. & Friedenberg, F. K. Cannabinoid hyperemesis syndrome. Curr. Drug Abuse Rev. 4, 241–249 (2011).

117. Cooper, C. J. et al. Rapid or normal gastric emptying as new supportive criteria for diagnosing cyclic vomiting syndrome in adults. Med. Sci. Monit. 20,1491–1495 (2014).

118. Venkatesan, T. et al. An Internet survey of marijuana and hot shower use in adults with cyclic vomiting syndrome (CVS). Exp. Brain Res. 232, 2563–2570 (2014).

119. Lacy, B. E., Parkman, H. P. & Camilleri, M. Chronic nausea and vomiting: evaluation and treatment. Am. J. Gastroenterol. 113, 647–659 (2018).

120. Homko, C. J., Duffy, F., Friedenberg, F. K., Boden, G. & Parkman, H. P. Effect of dietary fat and food consistency on gastroparesis symptoms in patients with gastroparesis. Neurogastroenterol. Motil. 27,501–508 (2015).

121. Olausson, E. A. et al. A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: a randomized controlled trial. Am. J. Gastroenterol. 109, 375–385 (2014). This important clinical trial demonstrates the importance of attention to particle size in the diet in patients with gastroparesis.

122. Pasricha, P. J. et al. Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin. Gastroenterol. Hepatol. 9,567–576 (2011).

123. McCallum, R. W. & George, S. J. Gastric dysmotility and gastroparesis. Curr. Treat. Opt. Gastroenterol. 4,179–191 (2001).

124. Rao, A. S. & Camilleri, M. Review article: metoclopramide and tardive dyskinesia. Aliment. Pharmacol. Ther. 31, 11–19 (2010).

125. Parkman, H. P., Hasler, W. L. & Fisher, R. S. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 127, 1592–1622 (2004).

126. Parkman, H. P., Carlson, M. R. & Gonyer, D. Metoclopramide nasal spray reduces symptoms of gastroparesis in women, but not men, with diabetes: results of a phase 2B randomized study. Clin. Gastroenterol. Hepatol. 13, 1256–1263 (2015).

127. Maganti, K., Onyemere, K. & Jones, M. P. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am. J. Gastroenterol. 98,

259–263 (2003).

128. Dhir, R. & Richter, J. E. Erythromycin in the shortand long- term control of dyspepsia symptoms in patients with gastroparesis. J. Clin. Gastroenterol. 38, 237–242 (2004).

129. Thielemans, L. et al. Desensitization of the human motilin receptor by motilides. J. Pharmacol. Exp. Ther. 313, 1397–1405 (2005).

130. Chedid, V. et al. Characterization of upper gastrointestinal symptoms, gastric motor functions and associations in patients with diabetes at a referral center. Am. J. Gastroenterol. https://doi.org/10.1038/s41395-018-0234-1 (2018).

131. Tack, J., Janssen, P., Masaoka, T., Farre, R. & Van Oudenhove, L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin. Gastroenterol. Hepatol. 10,1239–1245 (2012).

132. Camilleri, M. et al. Efficacy and safety of relamorelin in diabetics with symptoms of gastroparesis: a randomized, placebo- controlled study. Gastroenterology 153, 1240–1250 (2017).

133. Lembo, A. et al. Relamorelin reduces vomiting frequency and severity and accelerates gastric emptying in adults with diabetic gastroparesis. Gastroenterology 151, 87–96 (2016).

134. Carbone, F. et al. A controlled, cross- over trial shows benefit of prucalopride for symptom control and gastric emptying enhancement in idiopathic gastroparesis. Gastroenterology 150, S213–S214 (2016).

135. Matsueda, K., Hongo, M., Tack, J., Saito, Y. & Kato, H. A placebo- controlled trial of acotiamide for mealrelated symptoms of functional dyspepsia. Gut 61,821–828 (2012).

136. Tack, J. et al. Long- term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open- label safety trial. Neurogastroenterol. Motil. 30,e13284 (2018).

137. Parkman, H. P. et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA 310, 2640–2649 (2013).

138. Talley, N. J. et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. Gastroenterology 149, 340–349 (2015).

139. Herrick, L. M. et al. Effects of amitriptyline and escitalopram on sleep and mood in patients with functional dyspepsia. Clin. Gastroenterol. Hepatol. 16, 401–406 (2018).

140. Anttila, S. A. & Leinonen, E. V. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 7, 249–264 (2001).

141. Malamood, M., Roberts, A., Kataria, R., Parkman, H. P. & Schey, R. Mirtazapine for symptom control in refractory gastroparesis. Drug Des. Devel. Ther. 11, 1035–1041 (2017).

142. Pasricha, P. J. et al. Aprepitant has mixed effects on nausea and reduces other symptoms in patients with gastroparesis and related disorders. Gastroenterology 154, 65–76 (2018).

143. Jacob, D. et al. Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant. Am. J. Physiol. Gastrointest. Liver Physiol. 313, G505–G510 (2017).

144. Mearin, F., Camilleri, M. & Malagelada, J. R. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology 90, 1919–1925 (1986).

This classic original article demonstrates pylorospasm in patients with diabetic gastroparesis.

145. Coleski, R., Anderson, M. A. & Hasler, W. L. Factors associated with symptom response to pyloric injection of botulinum toxin in a large series of gastroparesis patients. Dig. Dis. Sci. 54, 2634–2642 (2009).

146. Arts, J. et al. Clinical trial: a randomized- controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment. Pharmacol. Ther. 26,1251–1258 (2007).

147. Friedenberg, F. K., Palit, A., Parkman, H. P., Hanlon, A. & Nelson, D. B. Botulinum toxin A for the treatment of delayed gastric emptying. Am. J. Gastroenterol. 103,416–423 (2008).

148. Shlomovitz, E. et al. Early human experience with peroral endoscopic pyloromyotomy (POP). Surg. Endosc. 29, 543–551 (2015).

149. Khashab, M. A. et al. Gastric per- oral endoscopic myotomy for refractory gastroparesis: results from the first multicenter study on endoscopic pyloromyotomy (with video). Gastrointest. Endosc. 85, 123–128 (2017).

150. Rodriguez, J. H. et al. Per oral endoscopic pyloromyotomy for refractory gastroparesis: initial results from a single institution. Surg. Endosc. 31,5381–5388 (2017).

151. Malik, Z. et al. Gastric per oral endoscopic myotomy (G- POEM) for the treatment of refractory gastroparesis: early experience. Dig. Dis. Sci. 63, 2405–2412 (2018).

152. Gonzalez, J. M., Benezech, A., Vitton, V. & Barthet, M. G- POEM with antro- pyloromyotomy for the treatment of refractory gastroparesis: mid- term follow- up and factors predicting outcome. Aliment. Pharmacol. Ther. 46, 364–370 (2017).

153. Dacha, S. et al. Outcomes and quality- of-life assessment after gastric per- oral endoscopic pyloromyotomy (with video). Gastrointest. Endosc. 86,282–289 (2017).

154. Shada, A. L. et al. Laparoscopic pyloroplasty is a safe and effective first- line surgical therapy for refractory gastroparesis. Surg. Endosc. 30, 1326–1332 (2016).

155. Mancini, S. A., Angelo, J. L., Peckler, Z., Philp, F. H. & Farah, K. F. Pyloroplasty for refractory gastroparesis. Am. Surgeon 81, 738–746 (2015).

156. Toro, J. P. et al. Efficacy of laparoscopic pyloroplasty for the treatment of gastroparesis. J. Am. Coll. Surgeons 218, 652–660 (2014).

157. Heckert, J., Sankineni, A., Hughes, W. B., Harbison, S. & Parkman, H. Gastric electric stimulation for refractory gastroparesis: a prospective analysis of 151 patients at a single center. Dig. Dis. Sci. 61, 168–175 (2016).

158. Ishii, M. et al. Altered postprandial insulin requirement in IDDM patients with gastroparesis. Diabetes Care 17, 901–903 (1994).

159. Parthasarathy, G. et al. Relationship between gastric emptying and diurnal glycemic control in type 1 diabetes mellitus: a randomized trial. J. Clin. Endocrinol. Metab. 102, 398–406 (2017).

160. Calles- Escandón, J. et al. Glucose sensor- augmented continuous subcutaneous insulin infusion in patients with diabetic gastroparesis: an open- label pilot prospective study. PLOS ONE 13, e0194759 (2018).

161. Farup, C. E. et al. Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care 21, 1699–1706 (1998).

162. Lacy, B. E., Crowell, M. D., Mathis, C., Bauer, D. & Heinberg, L. J. Gastroparesis: quality of life and health care utilization. J. Clin. Gastroenterol. 52, 20–24 (2018).

163. Yu, D. et al. The burdens, concerns, and quality of life of patients with gastroparesis. Dig. Dis. Sci. 62,879–893 (2017).

164. Jaffe, J. K., Paladugu, S., Gaughan, J. P. & Parkman, H. P. Characteristics of nausea and its effects on quality of life in diabetic and idiopathic gastroparesis. J. Clin. Gastroenterol. 45, 317–321 (2011).

165. Cherian, D., Sachdeva, P., Fisher, R. S. & Parkman, H. P. Abdominal pain is a frequent symptom of gastroparesis. Clin. Gastroenterol. Hepatol. 8, 676–681 (2010).

166. Friedenberg, F. K., Kowalczyk, M. & Parkman, H. P. The influence of race on symptom severity and quality of life in gastroparesis. J. Clin. Gastroenterol. 47, 757–761 (2013).

167. Woodhouse, S., Hebbard, G. & Knowles, S. R. Exploring symptom severity, illness perceptions, coping styles, and well- being in gastroparesis patients using the common sense model. Dig. Dis. Sci. 63, 958–965 (2018).

168. Tack, J., Rotondo, A., Meulemans, A., Thielemans, L. & Cools, M. Randomized clinical trial: a controlled pilot trial of the 5-HT4 receptor agonist revexepride in patients with symptoms suggestive of gastroparesis. Neurogastroenterol. Motil. 28, 487–497 (2016).

169. McCallum, R. W. et al. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clin. Gastroenterol. Hepatol. 8, 947–954 (2010).

170. Mekaroonkamol, P. et al. Gastric peroral endoscopic pyloromyotomy reduces symptoms, increases quality of life, and reduces healthcare usage for patients with gastroparesis. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2018.04.016 (2018).

171. Rajan, E. et al. Innovative gastric endoscopic muscle biopsy to identify all cell types, including myenteric neurons and interstitial cells of Cajal in patients with


Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí